ACS Chemical Neuroscience · 2018 · 30 citations · 27 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryNeuropharmacologyAlzheimer DiseaseBlood-brain Barrier PharmacologyCholinergic PharmacologyNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeuroprotectionAcetylcholinesterase InhibitorsAche InhibitionBiological Evaluation ReportCognitive Enhancement By Cholinergic AgentsDual-target InhibitorsNeurotoxicitySpatial MemorySpatial Memory Deficits
A series of dual-target AChE/PDE9A inhibitor compounds were designed, synthesized, and evaluated as anti-Alzheimer’s Disease (AD) agents. Among these target compounds, 11a (AChE: IC50 = 0.048 μM; PDE9A: IC50 = 0.530 μM) and 11b (AChE: IC50 = 0.223 μM; PDE9A: IC50 = 0.285 μM) exhibited excellent and balanced dual-target AChE/PDE9A inhibitory activities. Meanwhile, those two compounds possess good blood-brain barrier (BBB) penetrability and low neurotoxicity. Especially, 11a and 11b could ameliorate learning deficits induced by scopolamine (Scop). Moreover, 11a could also improve cognitive and spatial memory in Aβ25–35-induced cognitive deficit mice in the Morris water-maze test. In summary, our research developed a series of potential dual-target AChE/PDE9A inhibitors, and the data indicated that 11a was a promising candidate drug for the treatment of AD.
27
A new and rapid colorimetric determination of acetylcholinesterase activity
George L. Ellman, K. Diane Courtney, Valentino Andres et al. · Biochemical Pharmacology · 1961 · 26.9K citations